OPRM1, opioid receptor mu 1, 4988

N. diseases: 370; N. variants: 42
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE To deal successfully with the opioid crisis, we need to discover novel analgesics whose mechanisms do not involve the mu opioid receptor but that have high analgesic potency and low risk of adverse effects, particularly no abuse liability.The question is how to achieve this. 31399256 2020
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE Future studies with ICSS could help (a) to clarify mechanisms that increase MOR agonist abuse potential during early opioid exposure or during chronic exposure leading to dependence, (b) to evaluate novel opioids either developed as candidate analgesics with reduced abuse potential or identified as designer opioids being synthesized and distributed for illicit use, and (c) to test candidate pharmacotherapies for treatment of opioid abuse in non-dependent and dependent subjects. 30391425 2019
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE The combination of MOR agonists with non-MOR agonists may increase the analgesic potency of MOR agonists, reduce the development of tolerance and dependence, reduce the diversion and abuse, overdose, and reduce other clinically significant side effects associated with prolonged opioid use such as constipation. 31029588 2019
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 GeneticVariation group BEFREE The OPRM1 rs1799971" genes_norm="4988">A118G single nucleotide polymorphism (SNP rs1799971) gene variant encoding the rs1799971" genes_norm="4988">N40D µ-opioid receptor (MOR) has been associated with dependence on opiates and other drugs of abuse but its mechanism is unknown. 31481756 2019
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE This study assessed the impact of one synthetic cannabinoid, JWH-018, on the effects of two μ opioid receptor agonists using two procedures that address different aspects of abuse. 31295696 2019
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE The δ opioid receptor (δR) is a promising alternate target for pain management because δR agonists show decreased abuse potential compared with current opioid analgesics that target the μ opioid receptor. 28264976 2017
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group CTD_human Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. 27192616 2016
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE The μ-opioid receptor (MOR) binds exogenous and endogenous opioids and is known to mediate the rewarding effects of drugs of abuse. 23454283 2013
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 GeneticVariation group BEFREE We conclude that the TT genotype of OPRM1 may increase the risk of substance use and abuse. 21070507 2012
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE The rewarding properties of drugs of abuse are mediated by the mu-opioid receptor (MOR). 22472784 2012
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE These results support the hypothesis that genetic variability in the μ-opioid receptor gene influences the subjective effects of amphetamine and may suggest new strategies for prevention and treatment of psychostimulant abuse. 21029375 2011
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE Evidence points to the endogenous opioid system, and the mu-opioid receptor (MOR) in particular, in mediating the rewarding effects of drugs of abuse, including nicotine. 21576462 2011
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE The recently shown efficacy of these analgesics combined with a possible lower abuse potential and side effect burden than mu opioid receptor agonists makes delta and peripherally restricted kappa opioid receptor agonists promising targets for treating pain. 20026960 2010
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 GeneticVariation group BEFREE A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. 11840318 2002
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE The mu opioid receptor is implicated in the reward, tolerance and withdrawal effects of alcohol and other drugs of abuse. 9399694 1998
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.400 Biomarker group BEFREE Opioidergic neurotransmission and, specifically, the mu opioid receptor have been implicated in the reinforcing effects of a variety of drugs of abuse. 9756053 1998